.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,915,310

« Back to Dashboard

Details for Patent: 7,915,310

Title:Utilization of dialkylfumarates
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s): Joshi; Rajendra Kumar (Zurich, CH), Strebel; Hans-Peter (Muri, CH)
Assignee: Biogen Idec International GmbH (Zug, CH)
Filing Date:Mar 17, 2009
Application Number:12/405,665
Claims:1. A pharmaceutical preparation for treating enteritis regionalis Crohn, comprising: at least one excipient, at least one carrier, or a combination thereof; and an active ingredient in an amount effective to treat enteritis regionalis Crohn, wherein the only active ingredient for the treatment of enteritis regionalis Crohn present in said pharmaceutical preparation is dimethyl fumarate.

2. The pharmaceutical preparation of claim 1, wherein the active ingredient is present in an amount of from 10 to 300 mg.

3. The pharmaceutical preparation of claim 1, wherein the active ingredient is provided in one or more capsules.

4. The pharmaceutical preparation of claim 1, wherein the active ingredient consists of at least 50 mg of dimethyl fumarate.

5. The pharmaceutical preparation of claim 1, wherein the active ingredient consists of at least 110 mg of dimethyl fumarate.

6. The pharmaceutical preparation of claim 1, wherein the active ingredient consists of at least 120 mg of dimethyl fumarate.

7. The pharmaceutical preparation of claim 1, wherein the active ingredient consists of 50 mg of dimethyl fumarate.

8. The pharmaceutical preparation of claim 1, wherein the active ingredient consists of 110 mg of dimethyl fumarate.

9. The pharmaceutical preparation of claim 1, wherein the active ingredient consists of 120 mg of dimethyl fumarate.

10. The pharmaceutical preparation of claim 1, wherein the pharmaceutical preparation is formulated for oral administration.

11. The pharmaceutical preparation of claim 1, wherein the pharmaceutical preparation is formulated as a solid dosage form.

12. The pharmaceutical preparation of claim 1, wherein the pharmaceutical preparation is in the form of microtablets.

13. The pharmaceutical preparation of claim 12, wherein the microtablets are provided in one or more capsules, wherein at least 50 mg of dimethyl fumarate is present in each capsule.

14. The pharmaceutical preparation of claim 13, wherein at least 110 mg of dimethyl fumarate is present in each capsule.

15. The pharmaceutical preparation of claim 14, wherein at least 120 mg of dimethyl fumarate is present in each capsule.

16. The pharmaceutical preparation of claim 12, wherein the microtablets are enteric-coated.

17. The pharmaceutical preparation of claim 12, wherein the microtablets have a mean diameter in the range of 0.3 mm to 2.0 mm, exclusive of any coating on the microtablets.

18. The pharmaceutical preparation of claim 17, wherein the microtablets have a mean diameter of 2.0 mm, exclusive of any coating on the microtablets.

19. The pharmaceutical preparation of claim 1, wherein the pharmaceutical preparation comprises at least one carrier.

20. The pharmaceutical preparation of claim 1, wherein the pharmaceutical preparation comprises at least one excipient.

21. The pharmaceutical preparation of claim 1, wherein the pharmaceutical preparation comprises at least one excipient and at least one carrier.

22. A method of treating enteritis regionalis Crohn comprising treating a patient in need of treatment for enteritis regionalis Crohn with an amount of a pharmaceutical preparation effective for treating said enteritis regionalis Crohn, wherein the only active ingredient for the treatment of enteritis regionalis Crohn present in said pharmaceutical preparation is dimethyl fumarate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc